Biblio

Author Title Type [ Year(Asc)]
Filters: Author is De Philippis, Chiara  [Clear All Filters]
2024
Mariotti J, Zucchinetti C, Giordano L, De Philippis C, Mannina D, Sarina B, Taurino D, Carbon R, Santoro A, Bramanti S. Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort. Cytotherapy. 2024.
Lambri N, Longari G, Loiacono D, Brioso RCoimbra, Crespi L, Galdieri C, Lobefalo F, Reggiori G, Rusconi R, Tomatis S, et al. Deep learning-based optimization of field geometry for total marrow irradiation delivered with volumetric modulated arc therapy. Med Phys. 2024.
2023
Di Vito C, Coianiz N, Calvi M, Terzoli S, Zaghi E, Puccio S, Frigo A, Mariotti J, De Philippis C, Mannina D, et al. Persistence of KIR NK cells after haploidentical hematopoietic stem cell transplantation protects from human cytomegalovirus infection/reactivation. Front Immunol. 2023;14:1266051.
2022
Mariotti J, Magri F, Giordano L, De Philippis C, Sarina B, Mannina D, Taurino D, Santoro A, Bramanti S. EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
van Beek JJP, Puccio S, Di Vito C, De Paoli F, Zaghi E, Calvi M, Scarpa A, Peano C, Basso G, Cibella J, et al. Selected memory T cells infused post haploidentical hematopoietic stem cell transplantation persist and hyper-expand. Blood Adv. 2022.
2021
Bramanti S, De Philippis C, Bartoli A, Giordano L, Mariotti J, Sarina B, Mannina D, Valli V, De Gregori S, Roperti M, et al. Feasibility and efficacy of a PK-guided busulfan conditioning regimen for Allogeneic SCT with PTCY as GVHD prophylaxis in adult patients with hematologic malignancies. Transplant Cell Ther. 2021.
Castagna L, Valli V, Timofeeva I, Capizzuto R, Bramanti S, Mariotti J, De Philippis C, Sarina B, Mannina D, Giordano L, et al. Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. Transplant Cell Ther. 2021.
Sarina B, Mancosu P, Navarria P, Bramanti S, Mariotti J, De Philippis C, Clerici E, Franzese C, Mannina D, Valli V, et al. Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. Transplant Cell Ther. 2021.
2020
De Philippis C, Legrand-Izadifar F, Bramanti S, Giordano L, de Oca CMontes, Duléry R, Bouabdallah R, Granata A, Devillier R, Mariotti J, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020;4(7):1242-1249.
2019
Bramanti S, Calafiore V, Longhi E, Mariotti J, Crespiatico L, Sarina B, De Philippis C, Nocco A, Santoro A, Castagna L. Donor specific anti-HLA antibodies (DSA) in Haploidentical stem cell transplantation with Post Transplant Cyclophosphamide: risk of graft failure, poor graft function and impact on outcomes. Biol Blood Marrow Transplant. 2019.
Mariotti J, Taurino D, Marino F, Bramanti S, Sarina B, Morabito L, De Philippis C, Di Vito C, Mavilio D, Carlo-Stella C, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2019.